文献速递乳腺癌

CDK4/6抑制剂一线与二线治疗晚期乳腺癌的成本效果分析:SONIA试验

Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.
PubMed 文献 · Eur J Cancer · 2025-10-25

基于SONIA 3期试验患者数据,评估CDK4/6抑制剂一线 vs 二线联合内分泌治疗的成本效果。5年随访显示两组生命年和QALY无显著差异,但一线组医疗成本更高(差€22,764),ICER为€423,408/QALY。延迟至二线使用可大幅节约成本且健康产出相同。

要点

  • 一线与二线使用CDK4/6i的5年QALY差异无统计学意义(0.054,95%CI -0.143~0.250)。
  • 一线组医疗成本较二线组高€22,764(95%CI €18,815~€26,713),主要来自药物成本。
  • ICER为€423,408/QALY,延迟至二线使用可节约成本且疗效相当。

核心结论

  • 延迟CDK4/6i至二线治疗可大幅节约成本,且患者健康产出与一线使用相同。

研究设计与样本

  • 基于SONIA 3期试验患者水平数据的成本效果分析,随访5年,成本以2024年欧元计。

主要发现

  • 一线 vs 二线CDK4/6i的生命年为3.509(SE 0.075) vs 3.513(SE 0.084),差异-0.004(95%CI -0.232~0.223)。
  • QALY为2.694(SE 0.068) vs 2.644(SE 0.081),差异0.054(95%CI -0.143~0.250)。
  • 医疗成本为€61,821(SE 1423) vs €39,057(SE 1513),差异€22,764(95%CI €18,815~€26,713)。
  • 成本差异主要来自CDK4/6i药物成本(€24,699,95%CI €21,833~€27,564),二级护理就诊成本无差异。
  • ICER为€423,408/QALY,场景和敏感性分析结果相似。

临床怎么用

  • 对于HR阳性/HER2阴性晚期乳腺癌,可考虑将CDK4/6i延迟至二线联合氟维司群使用以节约成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SONIA phase 3 trial demonstrated adding cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) to first-line endocrine therapy (aromatase-inhibitor) was not superior in terms of progression-free survival after two treatment lines compared to addition to second-line (fulvestrant) in patients with hormone-receptor positive, HER2-negative advanced breast cancer. Although critical to inform decision-making, a detailed health economic evaluation of both treatment strategies is currently lacking. METHODS: We estimated the cost-effectiveness of CDK4/6i use in first- versus second-line over 5 years using patient-level data. Quality-adjusted life-years (QALYs) were estimated using EQ-5D-5L questionnaires. Hospital resource use was collected while on SONIA treatment and cancer medications until the end of follow-up. Costs are presented in 2024 Euros. Outcomes were adjusted for censoring (data cut-off 1 December 2022) and several scenario and sensitivity analyses were conducted. RESULTS: Estimated life-years were 3.509 [SE 0.075] versus 3.513 [SE 0.084]; difference -0.004, 95 % CI -0.232 to 0.223 in those receiving CDK4/6i in first- versus second-line, and QALYs were 2.694 [SE 0.068] versus 2.644 [SE 0.081]; difference 0.054, 95 % CI -0.143 to 0.250, respectively. Healthcare costs were higher among patients receiving CDK4/6i in first- versus second-line (€61,821 [SE 1423] versus €39,057 [SE 1513]; difference €22,764, 95 % CI €18,815 to €26,713). This was largely driven by higher CDK4/6i drug costs (€24,699, 95 % CI €21,833 to €27,564), with no differences in the costs of secondary care visits. The ICER was €423,408 per QALY gained. Scenario and sensitivity analyses showed similar results. CONCLUSION: Delaying CDK4/6i treatment to second-line leads to large cost savings while achieving the same patient health outcomes. TRIAL REGISTRATION: The SONIA trial was registered at ClinicalTrials.gov (NCT03425838).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wortelboer N, Kent S, Konings IR, et al. Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial. Eur J Cancer. 2025. PMID: 41207182. doi:10.1016/j.ejca.2025.116051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。